PLoS ONE · 2022 · 12 citations · 17 references
PharmacyClinical PharmacyPharmacoeconomicsCost-effectiveness AnalysisOutcomes ResearchPharmacoeconomic ModelingCatheter ManagementComparative Effectiveness ModelingCost-effectiveness ComparisonCost-effectiveness ModelingIncremental Cost-effectiveness AnalysisIntravenous Access DevicesAdult Central Venous Access CareCost-effectivenessCost-effectiveness Analysis PerspectiveCost-effectiveness ImprovementPeripheral Intravenous Access CarePeripheral Intravenous Catheters
The objective of the study was to perform a cost-effectiveness analysis of bundled devices (BDs) versus standard devices (SDs) for the prevention of unscheduled peripheral venous catheter (PVC) removal due to complication from a French investigator-initiated, open-label, single center, randomized-controlled, two-by-two factorial trial (CLEAN-3 study). A 14-day time non homogeneous semi-markovian model was performed to be fitted to longitudinal individual patient data from CLEAN-3 database. This model includes five health states and eight transitional events; a base case scenario, two scenario analyses and bootstrap sensitivity analyses were performed. The cost-effectiveness criterion was the cost per patient with unscheduled PVC removal avoided. 989 adult (age≥18 years) patients were analyzed to compare the BDs group (494 patients), and the SDs group (495 patients). The assessed intervention was a combination of closed integrated catheters, positive displacement needleless-connectors, disinfecting caps, and single-use prefilled flush syringes compared with the use of open catheters and three-way stopcocks for treatment administration. For the base case scenario, an unscheduled 1st PVC removal before discharge was significantly more frequent in the SDs group (235 patients (47.5%) in the SDs group and 172 patients (34.8%) in the BDs group, p = 0.00006). After adjustment for 1st catheter time, the number of patients with unscheduled PVC removal per day was of 16 (95%CI: 15; 18) patients (out of 100) in the BDs group and of 26 (95%CI: 24; 28) patients (out of 100) in the SDs group. The mean cost per patient (adjusted on catheter-time) was of €144 (95%CI: €135-€154) for patients in the SDs group versus €102 (95%CI: €95-€109) for patients in the BDs group; the mean saving per patient was of €42 (95%CI: €32-€54). As a consequence, the assessed BDs strategy was less costly and more effective than the SDs strategy. Trail registration: CLEAN-3 study is registered with ClinicalTrials.gov, NCT03757143.
17
Better Bootstrap Confidence Intervals
Bradley Efron · Journal of the American Statistical Association · 1987 · 3.3K citations
Bootstrap confidence intervals
Thomas J. DiCiccio, Bradley Efron · Statistical Science · 1996 · 2.3K citations · Full text
Baruch Fischhoff · Operations Research · 1980 · 1.4K citations
The Markov Process in Medical Prognosis
J. Robert Beck, Stephen G. Pauker · Medical Decision Making · 1983 · 973 citations
Claire M. Rickard, Nicole Marsh, Joan Webster et al. · The Lancet · 2018 · 178 citations · Full text